Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 10/20 | 0.43 |
| ▸ | HTR7 | P34969 | 3/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 3/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4069096 | 0.96 | NTRK1 (0.43) | NTRK1HTR7ADRA1DADRA1AADRA1B | |
| SCHEMBL4149465 | 0.94 | IGF1R (0.44) | NTRK1HTR7ADRA1DADRA1AADRA1B | |
| SCHEMBL3338223 | 0.89 | NTRK1 (0.46) | NTRK1HTR7ADRA1DADRA1AADRA1B | |
| SCHEMBL4077936 | 0.86 | NTRK1 (0.43) | NTRK1HTR7ADRA1DADRA1AADRA1B | |
| SCHEMBL3341203 | 0.84 | NTRK1 (0.51) | NTRK1HTR7ADRA1DADRA1AADRA1B | |
| SCHEMBL4075878 | 0.82 | NTRK1 (0.49) | NTRK1JAK2JAK3 | |
| SCHEMBL4068246 | 0.80 | NTRK1 (0.50) | NTRK1IGF1RJAK2JAK3 | |
| SCHEMBL3339301 | 0.76 | NTRK1 (0.56) | NTRK1IGF1RJAK2JAK3 | |
| SCHEMBL4162039 | 0.75 | NTRK1 (0.62) | NTRK1IGF1RJAK2JAK3 | |
| SCHEMBL4158277 | 0.75 | NTRK1 (0.51) | NTRK1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1686999-B1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | P2RX3, DPYD, TYMP | NTRK1 3656/4885HTR7 845/4885ADRA1D 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.